ROCKET PHARMACEUTICALS, INC. (RCKT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-300M -200M -100M 0 100M 200M 300M Q4 '14: -7.7M Q1 '15: -9M Q2 '15: -10.5M Q3 '15: -13.9M Q4 '15: -20.4M Q1 '16: -27.5M Q2 '16: -32.6M Q3 '16: -37.9M Q4 '16: -7.6M Q1 '17: -307K Q2 '17: 5M Q3 '17: 8.9M Q4 '17: -19.8M Q1 '18: -31.3M Q2 '18: -42.7M Q3 '18: -51.3M Q4 '18: -71.2M Q1 '19: -75.7M Q2 '19: -79.2M Q3 '19: -83M Q4 '19: -76.2M Q1 '20: -81.3M Q2 '20: -86.5M Q3 '20: -94.7M Q4 '20: -134.3M Q1 '21: -149.4M Q2 '21: -159.9M Q3 '21: -182.2M Q4 '21: -167.2M Q1 '22: -170.6M Q2 '22: -190.8M Q3 '22: -199.6M Q4 '22: -224.3M Q1 '23: -244M Q2 '23: -258.5M Q3 '23: -265.5M Q4 '23: -259.7M Q1 '24: -264.8M Q2 '24: -269.8M Q3 '24: -273.8M Q4 '24: -273.2M Q1 '25: -270.2M Q2 '25: -267.7M Q3 '25: -250.5M Q4 '25: -231.7M Q1 '26: -215.9M Q2 '26: -191.6M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income TTM

-270M -180M -90M 0 90M 180M 270M Q4 '14: -9.5M Q1 '15: -8.8M Q2 '15: -8.4M Q3 '15: -62M Q4 '15: -68M Q1 '16: -76.6M Q2 '16: -82.9M Q3 '16: -38.1M Q4 '16: -7.6M Q1 '17: -183K Q2 '17: 5.2M Q3 '17: 9.6M Q4 '17: -19.4M Q1 '18: -32M Q2 '18: -44.5M Q3 '18: -53.9M Q4 '18: -74.5M Q1 '19: -78.6M Q2 '19: -81.5M Q3 '19: -84.7M Q4 '19: -77.3M Q1 '20: -82.5M Q2 '20: -88.8M Q3 '20: -98.6M Q4 '20: -139.7M Q1 '21: -155.2M Q2 '21: -164.7M Q3 '21: -185.7M Q4 '21: -169.1M Q1 '22: -171.9M Q2 '22: -191.7M Q3 '22: -199.4M Q4 '22: -221.9M Q1 '23: -237.2M Q2 '23: -248.5M Q3 '23: -252.7M Q4 '23: -245.6M Q1 '24: -249.3M Q2 '24: -253.3M Q3 '24: -258.1M Q4 '24: -258.7M Q1 '25: -258M Q2 '25: -257.3M Q3 '25: -240.9M Q4 '25: -223.1M Q1 '26: -209.4M Q2 '26: -17.2M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q4 '14: -9.7M Q1 '15: -9.9M Q2 '15: -11.9M Q3 '15: -13.4M Q4 '15: -17.4M Q1 '16: -24.4M Q2 '16: -28.4M Q3 '16: -33.2M Q4 '16: -37.3M Q1 '17: -32M Q2 '17: -26.1M Q3 '17: -21.1M Q4 '17: -16M Q1 '18: -23.8M Q2 '18: -31.4M Q3 '18: -39M Q4 '18: -53.8M Q1 '19: -58.2M Q2 '19: -66.5M Q3 '19: -65.7M Q4 '19: -64.7M Q1 '20: -70.9M Q2 '20: -74.9M Q3 '20: -81.3M Q4 '20: -74.6M Q1 '21: -76.7M Q2 '21: -93.2M Q3 '21: -103.3M Q4 '21: -121.2M Q1 '22: -136.1M Q2 '22: -136.6M Q3 '22: -153.1M Q4 '22: -178.1M Q1 '23: -196.5M Q2 '23: -208.3M Q3 '23: -221.6M Q4 '23: -194.9M Q1 '24: -194.2M Q2 '24: -197.2M Q3 '24: -192.1M Q4 '24: -209.7M Q1 '25: -208.7M Q2 '25: -203.8M Q3 '25: -202.1M Q4 '25: -190M Q1 '26: -179.6M Q2 '26: -170.3M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '16: -29M Q3 '16: -33.6M Q4 '16: -37.8M Q1 '17: -32.6M Q2 '17: -27.1M Q3 '17: -22M Q4 '17: -16.7M Q1 '18: -24.5M Q2 '18: -31.6M Q3 '18: -39.6M Q4 '18: -55.2M Q1 '19: -60.4M Q2 '19: -75.2M Q3 '19: -80.6M Q4 '19: -87.9M Q1 '20: -98.6M Q2 '20: -97.9M Q3 '20: -97.5M Q4 '20: -95.2M Q1 '21: -92.4M Q2 '21: -108.4M Q3 '21: -122.6M Q4 '21: -128.8M Q1 '22: -145.3M Q2 '22: -147.3M Q3 '22: -160.4M Q4 '22: -186.5M Q1 '23: -205.9M Q2 '23: -218.9M Q3 '23: -236.4M Q4 '23: -211.4M Q1 '24: -209.7M Q2 '24: -210.4M Q3 '24: -202.3M Q4 '24: -215.6M Q1 '25: -212.8M Q2 '25: -206.1M Q3 '25: -202.8M Q4 '25: -190.5M Q1 '26: -179.8M Q2 '26: -170.4M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q1 '20: 54.9M Q2 '20: 55.2M Q3 '20: 55.2M Q1 '21: 61.6M Q2 '21: 63.1M Q3 '21: 63.8M Q1 '22: 64.5M Q2 '22: 65.5M Q3 '22: 66.2M Q1 '23: 79.5M Q2 '23: 80.5M Q3 '23: 82.6M Q1 '24: 93.5M Q2 '24: 93.7M Q3 '24: 94.2M Q1 '25: 110.1M Q2 '25: 111M Q3 '25: 111.6M Q1 '26: 112.1M Q2 '26: 114.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '14: -13.53 Q1 '15: -10.66 Q2 '15: -7.00 Q3 '15: -6.06 Q4 '15: -2.71 Q1 '16: -2.88 Q2 '16: -3.06 Q3 '16: -0.99 Q4 '16: -1.11 Q1 '17: -1.12 Q2 '17: -1.28 Q3 '17: -1.86 Q4 '17: -2.85 Q1 '18: -2.88 Q2 '18: -2.79 Q3 '18: -2.20 Q4 '18: -1.88 Q1 '19: -1.89 Q2 '19: -1.87 Q3 '19: -1.85 Q4 '19: -1.58 Q1 '20: -1.60 Q2 '20: -1.67 Q3 '20: -1.82 Q4 '20: -2.52 Q1 '21: -2.72 Q2 '21: -2.82 Q3 '21: -3.08 Q4 '21: -2.67 Q1 '22: -2.69 Q2 '22: -2.97 Q3 '22: -3.05 Q4 '22: -3.26 Q1 '23: -3.32 Q2 '23: -3.31 Q3 '23: -3.19 Q4 '23: -2.92 Q1 '24: -2.85 Q2 '24: -2.77 Q3 '24: -2.73 Q4 '24: -2.73 Q1 '25: -2.63 Q2 '25: -2.51 Q3 '25: -2.25 Q4 '25: -2.01 Q1 '26: -1.87 Q2 '26: -0.17 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.